On May 18, 2015, the U.S. International Trade Commission ("Commission") issued a press release announcing their vote to institute an investigation of Certain Recombinant Factor VIII Products (Inv. No. 337-TA-956).
The investigation is based on an April 16, 2015 complaint filed by Baxter International Inc. of Deerfield, Illinois, Baxter Healthcare Corp. of Deerfield, Illinois, and Baxter Healthcare SA of Switzerland alleging violation of Section 337 in the importation into the U.S. and sale of certain recombinant factor VIII products that infringe one or more claims of U.S. Patent Nos. 6,100,061; 6,936,441; and 8,084,252. See our April 17, 2015 post for more details on the complaint.
According to the Notice of Investigation, the Commission has identified Novo Nordisk A/S of Denmark and Novo Nordisk Inc. of Plainsboro, New Jersey as the respondents.
Lastly, Chief ALJ Bullock issued a notice indicating that Dee Lord will be the presiding Administrative Law Judge in this matter.